Sonoma exits going-concern doubt on 37% revenue surge, retail expansion; Mexico tax extended

The company launched a burn relief hydrogel into major U.S. retail chains (CVS, Walmart) in March 2026, representing a significant expansion into consumer retail channels. This is a new distribution milestone not present in the prior filing.

The company launched Aquanil AD, a new exclusive product line for Persōn & Covey, expanding its OTC dermatology presence through an established partner's distribution network. This represents a new partnership and product line not disclosed in the prior period.

The company registered its manufacturing facility and listed a Microcyn-based facial spray under the FDA's new MoCRA framework, which became effective in December 2022. This represents compliance with expanded FDA cosmetics authority and entry into the cosmetics regulatory category.

The company launched a new wound cleanser product with Medline for distribution into hospital systems and home healthcare channels, expanding the product portfolio under the existing Medline partnership announced in August 2024.

Reliefacyn received two new third-party endorsements (NPF Seal of Recognition in August 2025, NRS Seal of Acceptance in November 2025), adding to the National Eczema Association seal received in 2023. These endorsements strengthen the product's credibility for psoriasis and rosacea indications.

The company launched HOCl-based diaper rash products into Walmart and other large U.S. retailers in August 2025, representing a new product category (infant/child care) and further expansion into mass-market retail channels.

The company expanded its existing U.S. distributor partnership (originally announced with WellSpring in January 2025) to include additional consumer-focused products, broadening the product range available through large retail channels.

The company launched acne products into over 1,200 U.K. stores through a leading health and beauty retailer, representing a significant international retail expansion. This milestone was mentioned in the baseline's business updates but is now integrated into the ongoing business narrative.

The company received regulatory approval to sell wound care products in Ukraine as a Class IIb medical device, expanding its geographic regulatory footprint into a new market.

The entire "Oral, Dental and Nasal Care" business channel section was removed from the current filing. The baseline described Microdacyn60 Oral Care (for mouth/throat infections, thrush) and Sinudox (nasal irrigation) products sold internationally. The current filing no longer lists oral/nasal care as a business channel in the overview or competition sections, and the product descriptions are absent. This represents a strategic exit from or de-emphasis of these product lines.

The company removed "oral care" from the list of product applications in the overview section, aligning with the removal of the entire Oral, Dental and Nasal Care business channel. This reflects a narrowing of the company's stated product scope.

The company removed "nasal and oral care" from the list of competitive channels and simplified "eye, nasal and oral care" to "eye care" and "wound and acute care" to "wound care." This reflects the exit from oral/nasal product lines and a streamlined channel focus.

The company revised the description of dermatology product targets from "treatment of redness and irritation" to "relieving pain and itch from skin irritations," emphasizing symptom relief (pain, itch) over treatment of visual symptoms (redness). This is a tone shift toward patient-centric benefit language.

The company broadened the geographic description from "Europe and Asia" to "international markets," reflecting a more global distribution footprint or a shift away from region-specific disclosure. This is a minor wording change with no material impact.

The company removed the claims "reduce redness and irritation, and manage blemishes by reducing infection" from the Lumacyn product description, leaving only "soothe and cleanse the skin." This may reflect regulatory feedback, a shift to cosmetics positioning (MoCRA registration), or a decision to avoid infection-related claims for an OTC/cosmetic product.

The company removed detailed symptom language ("helps manage red, itchy, crusty and inflamed eyes") and efficacy claims ("strong enough to kill the bacteria... fast enough to provide near instant relief") from the Acuicyn description, leaving a more concise statement. This may reflect a shift to more conservative product positioning or regulatory considerations.

The company removed the claims "management of foot odors, infections, and irritations" from the Podiacyn description, leaving only "daily foot health and hygiene." This is consistent with the pattern of removing infection-related claims from OTC product descriptions, possibly reflecting a shift to more conservative positioning or regulatory considerations.

The company changed "treats a wide spectrum of animal wounds and infections" to "supports healing of a wide spectrum of animal wounds and infections," softening the claim from "treats" to "supports healing." This is a tone shift toward more conservative efficacy language.

The company removed extensive detail about Nanocyn's COVID-19 approvals (Australia, Canada), EPA List N/Q/G/H registrations, Green Seal certification, and the MicroSafe U.S. distribution agreement. This is a lifecycle removal: COVID-19-specific approvals and the 2021-2023 EPA registration milestones are no longer current news, and the product is now in steady-state distribution. The removal reflects normal housekeeping as the pandemic recedes and the product transitions from launch to ongoing operations.

The company increased U.S. full-time employees from 7 to 9 (net +2) and Mexico employees from approximately 160 to approximately 250 (net +90). The Mexico headcount increase of ~56% likely reflects manufacturing capacity expansion to support the new consumer retail launches and increased production volume.

R&D expense increased from $1,814,000 in FY2025 to $2,271,000 in FY2026, a 25% increase ($457,000). This reflects continued investment in the company's HOCl technology pipeline and new product development to support the expanded consumer retail and international launches.

Customer concentration shifted: FY2026 revenue concentration is lower (customer C at 15% vs. FY2025 customer B at 21% and customer C at 18%), and A/R concentration at March 31, 2026 is split between customer A (12%) and customer C (19%) vs. customer D (24%) at March 31, 2025. This reflects a more diversified customer base, consistent with the expansion into multiple retail channels (CVS, Walmart, Medline, U.K. retailer).

The company added a new "Cosmetics Regulation" section describing the FDA's MoCRA framework, which became effective in December 2022. This reflects the company's October 2025 registration of its manufacturing facility and listing of a Microcyn-based facial spray as a cosmetic product, representing a new regulatory category and compliance obligation.

The company added a new "Consumer Markets" product category section, describing HOCl-based products (facial sprays, diaper rash, sunburn relief, first aid) marketed through U.S. distributors and retail brands. This reflects the strategic shift toward consumer retail channels (CVS, Walmart, etc.) and the expansion of the product portfolio beyond prescription and OTC medical devices.

The baseline filing contained an entire "Management's Remediation Measures" section describing active efforts to address identified material weaknesses in internal controls, including specific actions like hiring a CFO/Controller, separating preparation from review, implementing revenue recognition controls, and addressing tax accrual issues. This entire section is absent from the current filing, suggesting the company believes the material weaknesses have been fully remediated and no longer require disclosure.

The baseline filing included specific language about determining adequacy of spreadsheet controls, separation of duties, and revenue reporting analysis, along with a statement that controls had been working sufficiently long to remove the weakness. This detailed assessment language is removed from the current filing.

The baseline filing contained extensive language about remediation completion, management's conclusion that material weaknesses were remediated through testing, and confirmation that controls operated effectively for a sufficient period. This entire assessment is absent from the current filing, consistent with the company having moved past the remediation phase.

The baseline filing disclosed material changes to internal controls during Q4 FY2025 (consistent with ongoing remediation efforts), while the current filing states there were NO changes during Q4 FY2026. This shift from active control changes to stable controls indicates the company has completed its remediation program and is now operating with established, effective controls.

The baseline filing disclosed substantial doubt about the company's ability to continue as a going concern within one year. The current filing removes this disclosure entirely, replacing it with language stating management believes existing cash and operating plans are sufficient for the next twelve months and that the company has access to additional capital resources if needed.

Total revenue increased 37% year-over-year to $19.5 million from $14.3 million. U.S. revenue more than doubled (117% growth) driven by increased over-the-counter product sales and distributor expansion. Europe and Asia each grew 25%, while Latin America declined 20% due to timing of overflow manufacturing orders.

The maturity date for Mexico tax liability, intercompany debt, and related charges has been extended from 2027 to 2032, providing five additional years before these obligations come due. Management continues to state there are sufficient balance sheet assets to cover the obligation without interrupting operations.

The company narrowed its disclosure of critical accounting judgment areas from five items (accounts receivable, inventory, income taxes, equity transactions) to only income taxes. This suggests management no longer considers receivables, inventory, or equity valuation to require significant judgment, possibly reflecting improved operational stability or reduced complexity.

Net loss improved 8% to $3.2 million from $3.5 million. Loss per share improved to $(1.89) from $(2.79), reflecting both the reduced loss and a 36% increase in weighted-average shares outstanding (1,684k vs 1,241k) from equity issuances during the year.

Cash declined 55% to $2.4 million from $5.4 million year-over-year. Operating activities consumed $3.9 million in cash during FY2026 compared to only $88k in FY2025, driven by increased accounts receivable, prepaid expenses, and reduced accounts payable. Equity proceeds of $427k partially offset the operating cash burn.

The company recognized $374k in employee retention credit income during FY2026, following $245k recognized in FY2025. The baseline filing had projected approximately $350k in FY2026 ERC income; the actual amount of $374k came in slightly higher than forecast.

Management now forecasts $500k in capital expenditures for FY2027 to purchase efficiency-enhancing equipment. The baseline filing stated no material capex was anticipated for FY2026. This represents a shift toward investing in operational capacity following the revenue growth achieved in FY2026.

The baseline filing emphasized uncertainty about securing additional capital and the potential need for cost reductions if capital is unavailable. The current filing adopts a more confident tone, stating existing cash is sufficient for twelve months and framing future capital raises as optional strategic choices rather than survival necessities. The cautionary language about inability to secure capital has been removed.

The company narrowed its disclosure of significant estimates from four items (receivables reserves, inventory write-downs, deferred tax valuation allowance, equity valuation) to only the deferred tax valuation allowance. This aligns with the earlier narrowing of critical judgment areas and suggests reduced estimation uncertainty in receivables, inventory, and equity.

The auditor's FY2025 opinion contained a separate "Substantial Doubt About the Company's Ability to Continue as a Going Concern" paragraph citing losses, negative cash flows, and need for additional capital. The FY2026 opinion omits this paragraph entirely. Management now states liquidity is sufficient for at least twelve months, citing the Dawson offering and improved cash management.

FY2025 Note 2 stated substantial doubt about going concern and described potential need for cost reductions and commercialization delays. FY2026 Note 2 affirmatively concludes existing cash plus Dawson proceeds are sufficient for at least twelve months, explicitly noting the conclusion "differs from prior periods" due to improved liquidity and cost alignment. The company no longer frames future capital as a necessity but as an option for growth.

Total revenue increased from $14.3M in FY2025 to $19.5M in FY2026, a 37% year-over-year increase. Human Care product revenue grew from $12.1M to $17.7M (46% increase), while Animal Care rose modestly from $1.7M to $1.8M. The prior-year comparison (FY2024: $12.7M) shows consistent growth trajectory.

Operating cash outflow increased sharply from $88K in FY2025 to $3.9M in FY2026. The deterioration is driven by working capital changes: prepaid expenses increased $1.3M (primarily VAT prepaid to Mexican tax authorities fell from $3.1M to $1.5M, but other prepaid rose), inventories increased $465K, and deferred revenue declined $452K. Despite 37% revenue growth, cash conversion worsened materially.

Note 2 discloses a $4.0M equity offering that closed April 27-28, 2026 (post-period), yielding $3.6M net proceeds. The offering included common stock, pre-funded warrants (all exercised by May 1, 2026), and warrants exercisable at $1.35 through April 2031. This capital raise is cited as the primary reason management removed going-concern doubt. The offering diluted shares outstanding by approximately 165% (from 1.8M to ~4.8M pro forma).

Note 11 newly quantifies the contingent Mexico tax liability at $16.5M (30% income tax on $55M of intercompany debt/accruals if forgiven or converted to equity), plus $5.6M in withholding tax on accrued interest and technical assistance. The intercompany loans were extended 5 years to 2032 maturity during FY2026. The baseline filing did not disclose this Mexico tax exposure in the notes (though withholding tax payable of $5.1M appeared on the balance sheet). The $16.5M contingent liability is new disclosure.

Withholding tax payable (non-current liability) increased from $5.1M at March 2025 to $5.6M at March 2026, reflecting continued accrual of 15% Mexican withholding tax on intercompany interest and technical assistance. The company cannot claim U.S. tax credits for these withholdings due to substantial NOLs, making the liability economically real.

Net loss improved from $3.5M in FY2025 to $3.2M in FY2026, despite 37% revenue growth. Gross profit increased $2.0M (from $5.5M to $7.4M), but operating expenses rose $701K (R&D up $457K, SG&A up $244K). Other expense swung from $803K income in FY2025 to $958K expense in FY2026, and income tax shifted from $550K expense to $244K benefit. The prior-year comparison (FY2024: $4.8M loss) shows consistent improvement trajectory.

Cash declined from $5.4M at March 2025 to $2.4M at March 2026, driven by $3.9M operating cash outflow partially offset by $427K from ATM equity sales and $44K from option exercises. The Dawson offering (post-period) added $3.6M, bringing pro forma cash to approximately $6.0M. Uninsured deposits fell from $3.0M to $1.5M.

Net inventory increased from $2.9M at March 2025 to $3.7M at March 2026 (26% increase), driven by finished goods rising from $1.8M to $2.5M (39% increase) while raw materials fell from $1.4M to $1.1M. Obsolescence reserve increased from $298K to $614K. The inventory build appears to support the 37% revenue growth, though the finished-goods concentration suggests potential demand-timing risk.

The FY2025 revenue recognition policy included a paragraph describing consignment arrangements with variable revenue recognition based on patient insurance status. This paragraph is absent from the FY2026 policy. The removal suggests the company exited consignment arrangements during FY2026, simplifying revenue recognition to direct sales and distributor models only.

The FY2025 revenue recognition policy included a paragraph describing the Invekra technical support contract and deferred revenue balances. This paragraph is absent from FY2026. Total deferred revenue fell from $658K at March 2025 to $284K at March 2026, suggesting the Invekra contract was substantially completed or terminated during FY2026. This is a lifecycle removal — the contract was a discrete arrangement that has now concluded.

Net deferred tax asset increased from $589K at March 2025 to $884K at March 2026, driven by Netherlands operations. The FY2025 filing noted the company released the Netherlands valuation allowance in FY2024 due to recent and anticipated earnings. The FY2026 increase reflects continued Netherlands profitability. U.S. deferred tax assets remain fully reserved due to NOLs.

Stock-based compensation expense increased modestly from $224K in FY2025 to $255K in FY2026. The prior-year comparison (FY2024: $516K) shows FY2025 was unusually low. FY2026 granted 74,500 options at $3.54 weighted-average fair value (vs. 49,500 at $2.68 in FY2025) and 96,500 restricted shares at $3.14 (vs. 54,538 at $2.92 in FY2025). Unrecognized compensation cost fell from $250K to $225K.

The company adopted a new 2024 Equity Incentive Plan in August 2024 with 50,000 shares authorized plus automatic annual increases (lesser of 5% of outstanding shares or board-determined amount). The board approved an 81,713-share increase during FY2026. At March 31, 2026, 104,500 options were outstanding under the 2024 Plan and 49,713 shares remained available. This supplements the existing 2016 and 2021 plans.

The FY2025 baseline filing opened with a going-concern risk factor stating that the audited financials "included disclosure that casts substantial doubt regarding our ability to continue as a going concern." The FY2026 current filing omits this entire risk factor. The removal indicates that the auditor no longer expressed substantial doubt about the company's ability to continue as a going concern for the FY2026 audit period — a material improvement in the company's financial position or liquidity outlook.

The company extended the maturity of its intercompany loans from 2027 to 2032 (a five-year extension) during FY2026. The outstanding principal increased from $10.9M to $12.3M, technical assistance from $8.6M to $10.4M, and accrued interest from $26.4M to $32.2M. The extension defers repayment pressure but the balances continue to grow, and the tax consequences (approximately $16.5M if forgiven or converted, up from $13.8M) also increased.

Customer concentration shifted: in FY2026, only customer C (15%) exceeded the 10% threshold, whereas in FY2025 both customer B (21%) and customer C (18%) were material. Customer B's share dropped below the disclosure threshold, indicating either reduced purchases by that customer or a more diversified revenue base. The company remains dependent on a small number of key customers.

International revenue as a percentage of total revenue declined from 82% in FY2025 to 71% in FY2026, an 11-percentage-point shift toward domestic sales. This could reflect stronger U.S. market penetration, weaker international demand, or foreign-exchange headwinds. The change materially alters the company's geographic risk profile and currency exposure.

Accounts receivable concentration shifted: at FY2026 year-end, customer A (12%) and customer C (19%) were the largest AR concentrations, whereas at FY2025 year-end customer D alone represented 24%. Customer D no longer appears above the 10% threshold, suggesting either collection or reduced sales to that customer. The shift to two customers (A and C) may indicate improved diversification or simply a timing difference in payment cycles.

The company disclosed a new proposed Nasdaq rule (filed January 2026) that would require a minimum $5 million market value of listed securities for continued listing on the Nasdaq Capital Market. If adopted, failure to maintain this threshold could result in immediate suspension and delisting without a compliance period. This is a new regulatory risk not present in the prior filing and could affect the company's listing status if its market capitalization falls below the threshold.

Outstanding stock options increased from 73,081 shares to 129,163 shares (a 77% increase), while the weighted average exercise price dropped from $43.27 to $23.94 (a 45% decline). The available share reserve for future grants increased from 14,670 to 82,290 shares. The lower exercise price and larger option pool suggest significant new grants at lower strike prices, likely reflecting a decline in the stock price during FY2026 and increased equity compensation to retain or attract employees.

The FY2025 baseline filing referenced outstanding warrants alongside options as a source of potential dilution and market overhang. The FY2026 current filing omits all references to warrants, mentioning only options. This suggests that outstanding warrants expired, were exercised, or were otherwise eliminated during FY2026, reducing one source of potential dilution.

The risk-factor heading and opening sentence were reworded. The baseline version framed the risk as "If our products fail to comply" (conditional), while the current version uses "Quality issues, concerns about safety or efficacy... could result" (more direct). The substance is the same — both describe recall risk and reputational harm — but the current version reads as slightly more assertive about the potential for quality or safety concerns to arise.